|
|
||||||||||
|
J Am Coll Cardiol, 2001; 37:371-378 © 2001 by the American College of Cardiology Foundation |

* Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Division of Cardiovascular Diseases, Mayo Clinic Jacksonville, Jacksonville, Florida, USA
Manuscript received March 29, 2000; revised manuscript received August 24, 2000, accepted October 4, 2000.
Reprint requests and correspondence: Dr. Bernard J. Gersh, Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55905
With a substantial impact on morbidity and mortality, the growing "epidemic" of atrial fibrillation (AF) intersects with a number of conditions, including aging, thromboembolism, hemorrhage, hypertension and left ventricular dysfunction. Currently, the epidemiology and natural history of AF govern all aspects of its clinical management. The ongoing global investigative efforts toward understanding AF are also driven by epidemiologic findings. New developments, by affecting the natural history of the disease, could eventually alter the nature of decision making in patients with AF. The crucial issue of rate versus rhythm control awaits completion of the AF Follow-up Investigation of Rhythm Management trial. The processes of electrical and structural remodeling that perpetuate AF appear to be reversible. In the era of functional genomics, the molecular basis of this ubiquitous arrhythmia is in the process of being defined. Unraveling the molecular genetics of AF might provide new insights into the structural and electrical phenotypes resulting from genetic mutations and, as such, new approaches to treatment of this arrhythmia at the ion channel and cellular levels. Thus, current adverse trends are superimposed on a background of a rapidly developing knowledge base and potentially exciting new therapeutic options. Consequently, an understanding of the epidemiology and natural history of AF is crucial to the future allocation of resources and the utilization of an expanding range of therapies aimed at reducing the impact of this disease on a changing patient population.
| ||||||||||||
This article has been cited by other articles:
![]() |
M. A. Groh, O. A. Binns, H. G. Burton III, G. L. Champsaur, S. W. Ely, and A. M. Johnson Epicardial Ultrasonic Ablation of Atrial Fibrillation During Concomitant Cardiac Surgery Is a Valid Option in Patients With Ischemic Heart Disease Circulation, September 30, 2008; 118(14_suppl_1): S78 - S82. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fatema, M. E. Barnes, K. R. Bailey, W. P. Abhayaratna, S. Cha, J. B. Seward, and T. S.M. Tsang Minimum vs. maximum left atrial volume for prediction of first atrial fibrillation or flutter in an elderly cohort: a prospective study Eur J Echocardiogr, September 11, 2008; (2008) jen235v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Baranchuk, C. S. Simpson, D. P. Redfearn, and M. Fitzpatrick It's time to wake up!: sleep apnea and cardiac arrhythmias Europace, June 1, 2008; 10(6): 666 - 667. [Full Text] [PDF] |
||||
![]() |
M. Meineri, R. Lavi, J. Carroll, J. Karski, and G. Djaiani 474858 - DIASTOLIC DYSFUNCTION AND POSTOPERATIVE ATRIAL FIBRILLATION IN PATIENTS UNDERGOING CORONARY REVASCULARIZATION SURGERY Can J Anesth, June 1, 2008; 55(suppl_1): 474858 - 474858. [Abstract] [Full Text] [PDF] |
||||
![]() |
G Y H Lip and C J Boos Antithrombotic treatment in atrial fibrillation Postgrad. Med. J., May 1, 2008; 84(991): 252 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. B. de Vos, R. Nieuwlaat, H. J.G.M. Crijns, A. J. Camm, J.-Y. LeHeuzey, C. J. Kirchhof, A. Capucci, G. Breithardt, P. E. Vardas, R. Pisters, et al. Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey Eur. Heart J., March 1, 2008; 29(5): 632 - 639. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Voeller, R. B. Schuessler, and R. J. Damiano Jr. Surgical Treatment of Atrial Fibrillation Card. Surg. Adult, January 1, 2008; 3(2008): 1375 - 1394. [Full Text] |
||||
![]() |
D. A. Lane and G. Y.H. Lip Barriers to Anticoagulation in Patients With Atrial Fibrillation: Changing Physician-Related Factors Stroke, January 1, 2008; 39(1): 7 - 9. [Full Text] [PDF] |
||||
![]() |
Y. Miyasaka, M. E. Barnes, R. C. Petersen, S. S. Cha, K. R. Bailey, B. J. Gersh, G. Casaclang-Verzosa, W. P. Abhayaratna, J. B. Seward, T. Iwasaka, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort Eur. Heart J., August 2, 2007; 28(16): 1962 - 1967. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Frost Lone Atrial Fibrillation: Good, Bad, or Ugly? Circulation, June 19, 2007; 115(24): 3040 - 3041. [Full Text] [PDF] |
||||
![]() |
A. Jahangir, V. Lee, P. A. Friedman, J. M. Trusty, D. O. Hodge, S. L. Kopecky, D. L. Packer, S. C. Hammill, W.-K. Shen, and B. J. Gersh Long-Term Progression and Outcomes With Aging in Patients With Lone Atrial Fibrillation: A 30-Year Follow-Up Study Circulation, June 19, 2007; 115(24): 3050 - 3056. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kotoh, K. Fukahara, T. Doi, S. Nagura, and T. Misaki Predictors of Early Postoperative Cerebral Infarction After Isolated Off-Pump Coronary Artery Bypass Grafting Ann. Thorac. Surg., May 1, 2007; 83(5): 1679 - 1683. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Miyasaka, M. E. Barnes, K. R. Bailey, S. S. Cha, B. J. Gersh, J. B. Seward, and T. S.M. Tsang Mortality Trends in Patients Diagnosed With First Atrial Fibrillation: A 21-Year Community-Based Study J. Am. Coll. Cardiol., March 6, 2007; 49(9): 986 - 992. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C.M. Choisy, L. A. Arberry, J. C. Hancox, and A. F. James Increased Susceptibility to Atrial Tachyarrhythmia in Spontaneously Hypertensive Rat Hearts Hypertension, March 1, 2007; 49(3): 498 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Decher, P. Kumar, T. Gonzalez, B. Pirard, and M. C. Sanguinetti Binding Site of a Novel Kv1.5 Blocker: A "Foot in the Door" against Atrial Fibrillation Mol. Pharmacol., October 1, 2006; 70(4): 1204 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Lombardi, M. Borggrefe, W. Ruzyllo, B. Luderitz, and for the A-COMET-II Investigators Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial Eur. Heart J., September 2, 2006; 27(18): 2224 - 2231. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Scanavacca, C. F. Pisani, D. Hachul, S. Lara, C. Hardy, F. Darrieux, I. Trombetta, C. E. Negrao, and E. Sosa Selective Atrial Vagal Denervation Guided by Evoked Vagal Reflex to Treat Patients With Paroxysmal Atrial Fibrillation Circulation, August 29, 2006; 114(9): 876 - 885. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Olson, A. E. Alekseev, X. K. Liu, S. Park, L. V. Zingman, M. Bienengraeber, S. Sattiraju, J. D. Ballew, A. Jahangir, and A. Terzic Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation Hum. Mol. Genet., July 15, 2006; 15(14): 2185 - 2191. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Miyasaka, M. E. Barnes, B. J. Gersh, S. S. Cha, K. R. Bailey, W. P. Abhayaratna, J. B. Seward, and T. S.M. Tsang Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence Circulation, July 11, 2006; 114(2): 119 - 125. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jahangiri, G. Weir, K. Mandal, I. Savelieva, and J. Camm Current strategies in the management of atrial fibrillation. Ann. Thorac. Surg., July 1, 2006; 82(1): 357 - 364. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. van der Hooft, J. Heeringa, G. G. Brusselle, A. Hofman, J. C. M. Witteman, J. H. Kingma, M. C. J. M. Sturkenboom, and B. H. Ch. Stricker Corticosteroids and the risk of atrial fibrillation. Arch Intern Med, May 8, 2006; 166(9): 1016 - 1020. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Korantzopoulos, T M Kolettis, A Papathanasiou, K K Naka, P Kolios, I Leontaridis, A Draganigos, C S Katsouras, and J A Goudevenos Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation Heart, May 1, 2006; 92(5): 631 - 634. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Miyasaka, M. E. Barnes, B. J. Gersh, S. S. Cha, K. R. Bailey, W. Abhayaratna, J. B. Seward, T. Iwasaka, and T. S.M. Tsang Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades Eur. Heart J., April 2, 2006; 27(8): 936 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. O. Arnar, S. Thorvaldsson, T. A. Manolio, G. Thorgeirsson, K. Kristjansson, H. Hakonarson, and K. Stefansson Familial aggregation of atrial fibrillation in Iceland Eur. Heart J., March 2, 2006; 27(6): 708 - 712. [Abstract] [Full Text] [PDF] |
||||
![]() |
G Y H Lip and C J Boos Antithrombotic treatment in atrial fibrillation Heart, February 1, 2006; 92(2): 155 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T. Ellinor, A. F. Low, and C. A. MacRae Reduced apelin levels in lone atrial fibrillation Eur. Heart J., January 2, 2006; 27(2): 222 - 226. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhang, Y. He, D. Tuteja, D. Xu, V. Timofeyev, Q. Zhang, K. A. Glatter, Y. Xu, H.-S. Shin, R. Low, et al. Functional Roles of Cav1.3({alpha}1D) Calcium Channels in Atria: Insights Gained From Gene-Targeted Null Mutant Mice Circulation, September 27, 2005; 112(13): 1936 - 1944. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Dixon, Y. Bracha, S. W. Loecke, M. A. Guerrero, R. D. Taylor, and R. W. Asinger Principal Atrial Fibrillation Discharges by the New ACC/AHA/ESC Classification Arch Intern Med, September 12, 2005; 165(16): 1877 - 1881. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Healey, A. Baranchuk, E. Crystal, C. A. Morillo, M. Garfinkle, S. Yusuf, and S. J. Connolly Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1832 - 1839. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Gersh, T. S.M. Tsang, M. E. Barnes, and J. B. Seward The changing epidemiology of non-valvular atrial fibrillation: the role of novel risk factors Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C5 - C11. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Vest, X. H.T. Wehrens, S. R. Reiken, S. E. Lehnart, D. Dobrev, P. Chandra, P. Danilo, U. Ravens, M. R. Rosen, and A. R. Marks Defective Cardiac Ryanodine Receptor Regulation During Atrial Fibrillation Circulation, April 26, 2005; 111(16): 2025 - 2032. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T. Ellinor, A. F. Low, K. K. Patton, M. A. Shea, and C. A. MacRae Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation J. Am. Coll. Cardiol., January 4, 2005; 45(1): 82 - 86. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. van der Hooft, J. Heeringa, G. van Herpen, J. A. Kors, J. H. Kingma, and B. H. Ch. Stricker Drug-induced atrial fibrillation J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2117 - 2124. [Abstract] [Full Text] [PDF] |
||||
![]() |
P T Ellinor, R K Moore, K K Patton, J N Ruskin, M R Pollak, and C A MacRae Mutations in the long QT gene, KCNQ1, are an uncommon cause of atrial fibrillation Heart, December 1, 2004; 90(12): 1487 - 1488. [Full Text] [PDF] |
||||
![]() |
P. L. L'Allier, A. Ducharme, P.-F. Keller, H. Yu, M.-C. Guertin, and J.-C. Tardif Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation J. Am. Coll. Cardiol., July 7, 2004; 44(1): 159 - 164. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Romano, D. S. Bach, F. D. Pagani, R. L. Prager, G. M. Deeb, and S. F. Bolling Atrial reduction plasty Cox maze procedure: extended indications for atrial fibrillation surgery Ann. Thorac. Surg., April 1, 2004; 77(4): 1282 - 1287. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Stewart, N Murphy, A Walker, A McGuire, and J J V McMurray Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK Heart, March 1, 2004; 90(3): 286 - 292. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Djaiani, B. Phillips-Bute, M. Podgoreanu, R. H. Messier, J. P. Mathew, F. Clements, and M. F. Newman The Association of Patent Foramen Ovale and Atrial Fibrillation After Coronary Artery Bypass Graft Surgery Anesth. Analg., March 1, 2004; 98(3): 585 - 589. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Fang, R. S. Stafford, J. N. Ruskin, and D. E. Singer National Trends in Antiarrhythmic and Antithrombotic Medication Use in Atrial Fibrillation Arch Intern Med, January 12, 2004; 164(1): 55 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Baldasseroni and A. P. Maggioni Authors reply to the letter titled: 'Mortality in congestive heart failure complicated by atrial fibrillation' Eur. Heart J., January 1, 2004; 25(1): 98 - 98. [Full Text] [PDF] |
||||
![]() |
L. Kristensen, J. C. Nielsen, P. T. Mortensen, A. K. Pedersen, and H. R. Andersen Evaluation of pacemaker telemetry as a diagnostic feature for detecting atrial tachyarrhythmias in patients with sick sinus syndrome Europace, January 1, 2004; 6(6): 580 - 585. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R Kasliwal, S. Mukesh, G. Manohar, N. Aggarwal, and A. Bhatia Pharmacotherapy of Atrial Fibrillation Asian Cardiovasc Thorac Ann, December 1, 2003; 11(4): 364 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Maurer Age: a nonmodifiable risk factor? J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1427 - 1428. [Full Text] [PDF] |
||||
![]() |
P. A Gould, M. D Esler, and D. M Kaye Chronic atrial fibrillation does not influence the magnitude of sympathetic overactivity in patients with heart failure Eur. Heart J., September 2, 2003; 24(18): 1657 - 1662. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Likosky, B. J. Leavitt, C. A. S. Marrin, D. J. Malenka, A. G. Reeves, R. M. Weintraub, L. R. Caplan, Y. R. Baribeau, D. C. Charlesworth, C. S. Ross, et al. Intra- and postoperative predictors of stroke after coronary artery bypass grafting Ann. Thorac. Surg., August 1, 2003; 76(2): 428 - 434. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mestroni Genomic medicine and atrial fibrillation J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2193 - 2196. [Full Text] [PDF] |
||||
![]() |
P. T. Ellinor, J. T. Shin, R. K. Moore, D. M. Yoerger, and C. A. MacRae Locus for Atrial Fibrillation Maps to Chromosome 6q14-16 Circulation, June 17, 2003; 107(23): 2880 - 2883. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Essebag, T. Hadjis, R. W. Platt, and L. Pilote Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction J. Am. Coll. Cardiol., January 15, 2003; 41(2): 249 - 254. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Chen, S.-J. Xu, S. Bendahhou, X.-L. Wang, Y. Wang, W.-Y. Xu, H.-W. Jin, H. Sun, X.-Y. Su, Q.-N. Zhuang, et al. KCNQ1 Gain-of-Function Mutation in Familial Atrial Fibrillation Science, January 10, 2003; 299(5604): 251 - 254. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Gorenek, G. Kudaiberdieva, O. Goktekin, Y. Cavusoglu, A. Birdane, A. Unalir, N. Ata, and B. Timuralp Long-short sequence may predict immediate recurrence of atrial fibrillation after external cardioversion Europace, January 1, 2003; 5(1): 11 - 16. [Abstract] [PDF] |
||||
![]() |
T. S. M. Tsang, B. J. Gersh, C. P. Appleton, A. J. Tajik, M. E. Barnes, K. R. Bailey, J. K. Oh, C. Leibson, S. C. Montgomery, and J. B. Seward Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1636 - 1644. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Williams, N. Hu, W. Shen, A. B. Mashburn, and K. T. Murray Modulation of the Human Kv1.5 Channel by Protein Kinase C Activation: Role of the Kvbeta 1.2 Subunit J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 545 - 550. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Stein, D. E. Euler, R. Mehra, K. Seidl, D. J. Slotwiner, S. Mittal, S. M. Markowitz, B. B. Lerman, and Jewel AF Worldwide Investigators Do atrial tachyarrhythmias beget ventricular tachyarrhythmias in defibrillator recipients? J. Am. Coll. Cardiol., July 17, 2002; 40(2): 335 - 340. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Palinkas, E. Antonielli, E. Picano, A. Pizzuti, A. Varga, B. Nyuzo, J.M. Alegret, A. Bonzano, M. Tanga, A. Coppolino, et al. Clinical value of left atrial appendage flow velocity for predicting of cardioversion success in patients with non-valvular atrial fibrillation Eur. Heart J., December 1, 2001; 22(23): 2201 - 2208. [Abstract] [PDF] |
||||
![]() |
M. Arndt, U. Lendeckel, C. Rocken, K. Nepple, C. Wolke, A. Spiess, C. Huth, S. Ansorge, H. U. Klein, and A. Goette Altered Expression of ADAMs (A Disintegrin And Metalloproteinase) in Fibrillating Human Atria Circulation, February 12, 2002; 105(6): 720 - 725. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Xu, H.-F. Tse, F. H.Y. Chan, P. C. W. Fung, K. L.-F. Lee, and C.-P. Lau New Bayesian Discriminator for Detection of Atrial Tachyarrhythmias Circulation, March 26, 2002; 105(12): 1472 - 1479. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |